Anti-Hypertensive Drugs: Market Research Report

Date: February 22, 2010
Pages: 893
Price:
US$ 3,950.00
Publisher: Global Industry Analysts, Inc
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: ABD53B5B0D1EN
Leaflet:

Download PDF Leaflet

Anti-Hypertensive Drugs: Market Research Report
This report analyzes the worldwide markets for Anti-Hypertensive Drugs in US$ Million.

The report provides separate comprehensive analytics for US, Europe and Rest of World.

Annual forecasts are provided for each region for the period 2007 through 2015.

Also, a six-year historic analysis is provided for these markets.

The report profiles 145 companies including many key and niche players worldwide such as AstraZeneca PLC, AstraZeneca PLC, Biovail Corp, Biovail Corp, Biovail Corp, Daiichi Sankyo Company, Limited, Dr. Reddy's Laboratories Ltd., Forest Laboratories, Inc., Forest Laboratories, Inc., Merck & Co., Inc., Mylan, Inc., Novartis AG,. Pfizer, Inc., Ranbaxy Laboratories Limited, Sanofi-aventis, Solvay Pharmaceuticals SA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Limited, and The Medicines Company.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.
I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1.MARKET AT A GLANCE

Introduction
Hypertension – Prevalence
Market Overview
Current and Future Analysis
ARBs Lead the World Anti-hypertension Drugs Market
Lack of R&D Innovation, Genericization Characterize the Global Anti-Hypertensive Drugs Market

2.HYPERTENSION: DEFINITION, CONCERNS, CONSEQUENCES, CATEGORIZATION, DIAGNOSIS, TREATMENT, SIDE EFFECTS, AND LEADING DRUGS

Definition
Blood Pressure
High Blood Pressure
Concerns
Consequences
Hypertension and Diabetic Population
Categorization
Primary and Secondary Hypertension
Acute Hypertension
Diagnosis
Treatment
Lifestyle Modifications
Avoiding Nicotine Products
Avoiding Alcohol
Avoiding Processed Foods
Restricting Sodium
Reducing Weight
Adopting Biofeedback / Relaxation Techniques
Anti-Hypertensive Drugs
Beta Blockers
Types of Beta-blockers
Calcium Channel Blockers
Types of Calcium Channel Blockers
Angiotensin II Receptor Blockers
Types of Angiotensin II Receptor Blockers
ACE Inhibitors
Types of ACE Inhibitors
Diuretics
Types of Diuretics
Other Anti-hypertensive Drugs
Renin Inhibitors
Vasodilators
Types of Vasodilators and Brand Names
Alpha Blockers
Mixed Blockers
Adrenergic Receptor Agonist
Aldosterone Receptor Antagonists
Central Alpha Agonists
Side Effects
Side Effects by Drug Class
Thiazide Diuretics
Beta-blockers
ACE Inhibitors
Peripheral Vasodilators
Side Effects by Drug Name
Side Effects Profile of Select Anti-hypertensive Drugs
Select Leading Anti-hypertensive Drugs: A Review
Benicar/Olmetec
Cleviprex
Cozaar
Diovan/Diovan HCT
Exforge
Norvasc
Tekturna/Rasilez
Tekturna HCT

3.RESEARCH & DEVELOPMENT

Takeda’s TAK-536 Reaches Phase III Clinical Trials in Japan
China Pharma Commences Clinical Trials for Candesartan Generic
Taipei Medical University Reveals Results of New Blood Pressure Study
Researchers Identify New Genes Affecting Blood Pressure
Italian Study Demonstrates Benefits of Investigational Amlodipine and Telmisartan Combination Treatment in Blood Pressure Patients Exposed to Risk of Cardiovascular Events
Gilead Sciences Announces Phase III Darusentan Data
Gilead Sciences Commences Phase II Trial of Cicletanine
New Clinical Data Demonstrates Effectiveness of Rasilez/ Tekturna in Obese Patients with Hypertension in Comparison to Monotherapy with Diuretic Hydrochlorothiazide
New Study Demonstrates Effectiveness of Exforge® in Controlling High Blood Pressure in 'difficult-to-treat' Patients than Amlodipine Alone
New Analyses Demonstrates Use of Cleviprex for Controlling Perioperative Hypertension to Lower the Risk of Heart Attack and Mortality Following Cardiac Surgery
Surface Logix Announces Encouraging Phase IIa Results of SLx-2101
Observational Study Demonstrates Telmisartan to Provide Powerful Blood Pressure Control for Complete 24-hours, Including the Risky Hours of Early Morning
New Study Demonstrates Tekturna® When Combined with Diovan® to Have Additional Blood Pressure Lowering Effect
Protherics Develops High Blood Pressure Vaccine

4.PRODUCT INTRODUCTIONS

Takeda Introduces ECARD for Hypertension Treatment
Amneal Pharmaceuticals Introduces Benazepril HCI
Ranbaxy Laboratories to Introduce Daiichi Sankyo's Olvance in India
Gemini Pharmaceuticals Launches Anti-hypertensive Medicine, Micardis
Shionogi Introduces Fluitran® 1mg
Helvepharm Launches New Anti-hypertensive Drug
Ranbaxy Laboratories Introduces Amlodipine
Nicholas Piramal Launches Hypertension Management Device
GlaxoSmithKline Introduces Ambrisentan
Novartis Introduces Aliskiren
Dainippon Introduces Avapro for Hypertension Treatment
Shionogi Introduces Irbetan for Hypertension Treatment
Pfizer Japan Introduces Sildenafil
Surgipharm Launches Diovan and Co-diovan
King Pharmaceuticals Introduces Altace Tablets
Encysive Pharmaceuticals Introduces Thelin Tablets
Dr Reddy's Laboratories Introduces Atocor-R
Wockhardt to Introduce Amlodipine Tablets
GlaxoSmithKline Launches Coreg CR Extended-Release Capsules
Toray and Astellas Introduce Careload LA Tablets
Encysive Introduces Sitaxentan Encysive
GlaxoSmithKline Introduces Carzec
Encysive Pharmaceuticals Introduces Thelin
Ranbaxy Laboratories Introduces Generic Drug Verapamil
Actavis Group Introduces NIFEdipine (XR) Tablets
Apotex Introduces Norvasc Generic
Novartis Introduces Aliskiren
Encysive Introduces Sitaxentan
Pfizer to Release the Generic Version of Norvasc
Mylan Introduces Generic Blood Pressure Medicines

5.RECENT INDUSTRY ACTIVITY

Sanofi-Aventis Takes Over Helvepharm
ARCA Biopharma Merges with Nuvelo
Astellas and Nippon Receive Approval for Micombi® Antihypertensive Drug
The Medicines Co Announces EU Acceptance of MAA for Cleviprex
Actelion and GeneraMedix Sign Definitive Agreement
AtCor Medical Enters into Contract with Pharmaceutical Company
Ranbaxy Receives FDA Approval for Anti-hypertensive Drug
Sun Pharmaceuticals Receives Approval for Generic Version of Accupril
Sucampo Pharma Americas Wins Rights to Rescula
Novartis Obtains Approval from Japanese Health Ministry
Novartis Obtains FDA Approval for Exforge HCT
Novartis Obtains Approval for Four New Medicines
Aveva Drug Delivery Obtains Approval for Clonidine TDS
Ranbaxy Receives Approval to Market Anti-Hypertension Drug
Actelion Receives FDA Approval for New Ventavis Formulation
Sinobiopharma Receives Chinese Approval for Perindopril
Pfizer Acquires Encysive Pharmaceuticals
GlaxoSmithKline Acquires Bristol Myers Squibb’s Egyptian Business
Gilead Sciences Acquires Navitas’ Cicletanine Business Assets
Shionogi Acquires Sciele Pharma
Recordati Acquires Yeni Ilac
Kyowa Hakko Merges with Kirin Pharma
Belupo and Farmavita Announce Merger
Daiichi Sankyo India and GlaxoSmithKline Sign Co-Promotion Deal
Sciele Pharma and Addrenex Pharmaceuticals Sign Exclusive Agreement
Merck Serono Signs Distribution Agreement with Bristol-Myers Squibb
Forest Laboratories Holdings Amends Agreement with Mylan
Speedel Secures FDA Approval for Tekturna HCT
Lupin Receives FDA Approval for Generic Ramipril Capsules
Daiichi Sankyo Submits Application for Anti-hypertensive Drug Approval
Mylan Receives FDA Approval for Nisoldipine Extended-Release
Glenmark Wins FDA Approval for Trandolapril
Novartis Obtains FDA Approval for Tekturna HCT
Mylan Receives Tentative Approval for Generic Version of Benicar HCT
Novartis Secures Swissmedic Approval for Rasilez HCT
Kyowa Secures Japanese Approval for Amlodipine Generic
Aurobindo Pharma Obtains FDA Approval
Actelion Receives EU Approval for Tracleer
The Medicines Company Wins FDA Approval for Cleviprex
Indian Pharmaceuticals Wins Approval for Propranolol Hydrochloride Tablets
Aurobindo Pharma Secures FDA Approval for Lotensin Generic
Zydus Cadila Obtains FDA Approval for Marketing of Benazepril
Mylan Wins FDA Approval for Mavik’s Generic
Kampala Pharma to Commence Production of High Blood Pressure Drugs
Merck Extends Licensing Agreement with AstraZeneca
Helpson Receives China FDA Approval to Market Bumetanide Generic
Sciele Pharma Obtains FDA Approval
DAIICHI SANKYO ILAC Acquires Anti-hypertensive Drug, Concor
Novartis’ Rasilez HCT Receives European Committee Recommendation
Pfizer Wins Patent Protection Lawsuit for Norvasc in Canada
Forest Labs and Daiichi Sankyo Terminate Azor Co-Promotion Agreement
Novartis Wins Canadian Approval for Rasilez
Hi-Tech Pharmacal Receives ANDA Approval from FDA
Dr. Reddy's Receives FDA Approval for Trandolapril
Quantum Genomics and PCAS Pharma Sign Strategic Agreement
GeneraMedix Wins Approval from FDA for Epoprostenol
Pharmaceutical Holdings Changes Name to URL Pharma
Zydus Cadila Obtains Approval from U.S. FDA for Ramipril Capsules
Zydus Cadila Obtains Approval from U.S. FDA for Four Drugs
KV Pharmaceutical Obtains FDA Approval for Toprol-XL Generic
Ranbaxy Pharmaceuticals and AstraZeneca Sign Agreements
Recordati Completes Mutual Recognition with 28 European Nations
Recordati Obtains Australian Approval for Zan-Extra®
Santen Pharmaceutical Obtains Approval for TAPROS
Santen Obtains Marketing Authorization for TAFLOTAN
Boehringer Ingelheim Wins EU Commission Approval for MicardisPlus® 80/25
Daiichi Sankyo Europe Obtains Marketing Approval of SEVIKAR®
Daiichi Sankyo Establishes Subsidiary in Ireland
GlaxoSmithKline Wins EC Marketing Approval for Volibris
NicOx Enters into Alliance with Royal DSM
NicOx Enters into Alliance with Archimica
NicOx Enters into Alliance with Capsugel
Novartis Obtains FDA Approval for Exforge and Diovan HCT
Actelion and Merck Initiate Phase II Program Dosing, Reach Fourth Milestone
Jupiter Bioscience Acquires Drug Technology
Recordati- Berlin Chemie Expand Licensing Agreement
Meda and Recordati Enter into Agreement for Zaneril®
Glenmark Wins FDA Approval for Coreg
Novartis Secures FDA Approval for Exforge
Caraco Receives ANDA Approval for Norvasc Generic
Mylan and Forest Labs Win FDA Approval to Market Bystolic
Daiichi Sankyo Secures FDA Approval for Azor
Teva Bags Approval to Market Accupril Generic
Meda and Recordati Sign Long-Term Agreement
Ranbaxy Bags Approval to Produce and Market Amlodipine Besylate
Caraco Receives FDA Approval for Atenolol Tablets
Sciele Pharma and Addrenex Enter into Agreement
Novartis Wins Swissmedic Approval for Tekturna
Lupin Bags Approval to Market Prinivil’s Generic Version
Aurobindo Pharma Receives FDA Approval for Accuretic’s Generic Version
Gilead Sciences Wins FDA Approval for Letairis
Guangdong Luote Signs Agreement with Nippon Chemiphar
Wockhardt Wins FDA Approval to Market Lisinopril
Kaken to Commence Marketing Procylin for Pulmonary Hypertension Treatment
Encysive Pharma Wins Australian Approval for THELIN®
Ranbaxy Wins Approval to Market Atenolol
Novartis Secures EC Approval for Exforge
Ranbaxy Receives Health Canada Approval for Lisinopril Tablets
Ranbaxy Receives Tentative Approval for Valsartan Tablets
Bristol-Myers and sanofi-aventis Obtain FDA Approval for AVALIDE
Par Pharmaceutical Receives FDA Approval for Propranolol HCl ER
Ranbaxy Receives Approval from FDA for Coreg Generic
KV Pharmaceuticals Obtains FDA Approval for Toprol-XL Generic
Mylan Wins Approval for Propranolol Hydrochloride ER Capsules
Novartis Wins EU Approval for Rasilez
Actavis Group Secures FDA Approval for Carvedilol Tablets
Par Pharmaceuticals Ships ER Metoprolol Succinate Tablets
Biovail Reaches Settlement Agreement with Watson Pharmaceuticals
Lexicon Genetics Announces Name Change

6.FOCUS ON SELECT MAJOR PLAYERS

AstraZeneca PLC (UK)
Bayer AG (Germany)
Biovail Corp. (Canada)
Boehringer Ingelheim GmbH (Germany)
Bristol-Myers Squibb Company (USA)
Daiichi Sankyo Company, Limited (Japan)
Dr. Reddy's Laboratories Ltd. (India)
Forest Laboratories, Inc. (USA)
GlaxoSmithKline PLC (UK)
Merck & Co., Inc. (USA)
Mylan, Inc. (USA)
Novartis AG (Switzerland)
Pfizer, Inc. (USA)
Ranbaxy Laboratories Limited (India)
Sanofi-aventis (France)
Solvay Pharmaceuticals SA (Belgium)
Takeda Pharmaceutical Company Limited (Japan)
Teva Pharmaceutical Industries Limited (Israel)
The Medicines Company (USA)

7.GLOBAL MARKET PERSPECTIVE

Table 1. World Recent Past, Current & Future Analysis for Anti-hypertensive Drugs by Geographic Region – US, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 2. World Historic Review Analysis for Anti-hypertensive Drugs by Geographic Region – US, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)
Table 3. World 15-Year Perspective for Anti-hypertensive Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for the US, Europe and Rest of World Markets for 2003, 2009 & 2015 (includes corresponding Graph/Chart)

III. MARKET

1.UNITED STATES

A. MARKET ANALYSIS

Hypertension - Prevalence

Table 4. Hypertension Prevalence Among Adults in the US – Percentage Share Breakdown by Age Group: 2005-2006 (includes corresponding Graph/Chart)
Table 5. Hypertension Prevalence Among Adults in the US – Percentage Share Breakdown by Gender: 2005-2006
Table 6. Hypertension Prevalence Among Adults in the US – Percentage Share Breakdown by Race/Ethnicity: 2005-2006 (includes corresponding Graph/Chart)
Table 7. Hypertension Treatment Among Hypertensive Adults in the US – Percentage Share Breakdown by Gender and Age Group: 2005-2006 (includes corresponding Graph/Chart)
Table 8. Hypertension Treatment Among Hypertensive Adults in the US – Percentage Share Breakdown by Race/Ethnicity: 2005-2006 (includes corresponding Graph/Chart)
Table 9. Outpatient Department Visit with Hypertension as Co-morbid Chronic Condition in the US – Percentage Share Breakdown by Age Group: 2006 (includes corresponding Graph/Chart)
Table 10. Outpatient Department Visits with Hypertension as Co-morbid Chronic Condition in the US – Percentage Share Breakdown by Gender: 2006

Market Overview

Table 11. US Anti-hypertensive Drugs Market – Sales and Percentage Share Breakdown by Leading Drugs in US$ Million Between October 2007 and October 2008 (includes corresponding Graph/Chart)
Table 12. US Anti-hypertensive Drugs Market – Percentage Share Breakdown of Leading Class of Drug Based on Total Prescriptions for 2007 (includes corresponding Graph/Chart)
Table 13. US Anti-hypertensive Drugs Market – Percentage Share Breakdown of ACE Inhibitors Based on Total Prescriptions for 2007 (includes corresponding Graph/Chart)
Table 14. US Anti-hypertensive Drugs Market – Percentage Share Breakdown of Angiotension Receptor Blockers (ARBs) Based on Total Prescriptions for 2007 (includes corresponding Graph/Chart)

New Patient Therapy Starts to Witness Slowdown

Table 15. US Anti-hypertensive Drugs Market – Percentage Share Breakdown of Angiotensin II Receptor Blockers by New Prescriptions for 2006, 2007 and 2008 (includes corresponding Graph/Chart)
Table 16. US Anti-hypertensive Drugs Market – Percentage Share Breakdown of ACE Inhibitors by New Prescriptions for 2006, 2007 and 2008 (includes corresponding Graph/Chart)
Table 17. US Anti-hypertensive Drugs Market – Percentage Share Breakdown of Calcium Channel Blockers by New Prescriptions for 2006, 2007 and 2008 (includes corresponding Graph/Chart)

African Americans At Major Health Risk Due to Hypertension
Research & Development
Product Launches
Strategic Corporate Developments
Select Players

B. MARKET ANALYTICS

Table 18. US Recent Past, Current & Future Analysis for Anti-hypertensive Drugs – Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 19. US Historic Review Analysis for Anti-hypertensive Drugs – Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

2.EUROPE

A. MARKET ANALYSIS

Hypertension – Prevalence
Non-Invasive Blood Pressure Monitoring on Growth Trajectory
Regional Markets at a Glance
United Kingdom
Hypertension – Prevalence
Hypertension Treatment – Monotherapy and Combination Therapies
Denmark
Cheaper Alternatives for Hypertension Treatment
Norway
New Branded Drugs Dominate Anti-hypertensive Drugs Market
New Amendments to Medicines Reimbursement
Proposed New Reimbursement Conditions in Norway
Research and Development
Product Launches
Strategic Corporate Developments
Select Players

B. MARKET ANALYTICS

Table 20. European Recent Past, Current & Future Analysis for Anti-hypertensive Drugs – Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 21. European Historic Review Analysis for Anti-hypertensive Drugs – Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

3.REST OF WORLD

A. MARKET ANALYSIS

Canada

Table 22. Canadian Anti-hypertensive Drugs Market – Total Number of Prescriptions in Thousands for 1996 and 2006 (includes corresponding Graph/Chart)

Japan
Australia
Australians to Shell Out More on Anti-Hypertensive Drugs
China
Hypertension – A Major Health Concern in China
Anti-hypertensive Drugs Market
Hypertension Outlook
Competitive Landscape
India
Anti-Hypertensive Drugs Manufacturers
Korea
Anti-hypertensive Drugs Market

Table 23. Korean Anti-hypertensive Drugs Market – Leading Classes of Drugs by Value Sales in US$ Million for 2007, 2008, and 2009 (Q1) (includes corresponding Graph/Chart)
Table 24. Korean Anti-hypertensive Drugs Market – Percentage Share Breakdown of Leading Drugs by Outpatient Prescription Value for 2007, 2008 and 2009 (H1) (includes corresponding Graph/Chart)

Anti-hypertension Drugs Market – Angiotensin Receptor Blockers

Table 25. Korean Anti-hypertensive Drugs Market – Percentage Share Breakdown of Leading Angiotension Receptor Blockers by Prescription Value for 2008 and 2009 (Q1) (includes corresponding Graph/Chart)

Anti-hypertension Drugs Market – Calcium Channel Blockers

Table 26. Korean Anti-hypertensive Drugs Market – Percentage Share Breakdown of Leading Calcium Channel Blocker by Prescription Value for 2008 and 2009 (Q1) (includes corresponding Graph/Chart)

Anti-hypertension Drugs Market – Beta-blockers

Table 27. Korean Anti-hypertensive Drugs Market – Percentage Share Breakdown of Leading Beta- blockers for 2008 and 2009 (Q1) (includes corresponding Graph/Chart)

Kenya
Anti-hypertensive Drugs Market
Manufacturing Overview
Generics Erode Share of Ethical Drugs
Research and Development
Product Launches
Strategic Corporate Developments
Select Players

B. MARKET ANALYTICS

Table 28. Rest of World Recent Past, Current & Future Analysis for Anti-hypertensive Drugs – Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 29. Rest of World Historic Review Analysis for Anti-hypertensive Drugs – Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 145 (including Divisions/Subsidiaries - 176)
Region/CountryPlayers
The United States
Canada
Japan
Europe
France
Germany
The United Kingdom
Italy
Spain
Rest of Europe
Asia-Pacific (Excluding Japan)
Latin America
Africa
Middle East
Skip to top


Anti-Migraine Drugs: Market Research Report US$ 3,950.00 Feb, 2010 · 580 pages
Research Report on Chinese Anti-Tumor Drug Market, 2009 US$ 1,160.00 Mar, 2009 · 60 pages
Hypertension Treatment Drugs Market Research (China) US$ 4,000.00 May, 2013 · 186 pages
Anti-Tumor Drugs Market Research (China) US$ 4,000.00 May, 2016 · 214 pages

Ask Your Question

Anti-Hypertensive Drugs: Market Research Report
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: